UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`AMNEAL PHARMACEUTICALS LLC, PAR PHARMACEUTICAL,
`INC., and WOCKHARDT BIO AG,
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner.
`
`_____________________
`
`IPR2015-005471
`Patent 7,765,107
`_____________________
`
`AMNEAL PHARMACEUTICALS LLC and
`PAR PHARMACEUTICAL, INC.’S EXHIBIT LIST
`
`
`
`
`
`Mail Stop "PATENT BOARD"
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`1 Case IPR2015-01820 has been joined with this proceeding.
`
`
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`AMNEAL PHARMACEUTICALS LLC, PAR PHARMACEUTICAL,
`INC., and WOCKHARDT BIO AG,
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner.
`
`_____________________
`
`IPR2015-005471
`Patent 7,765,107
`_____________________
`
`AMNEAL PHARMACEUTICALS LLC and
`PAR PHARMACEUTICAL, INC.’S EXHIBIT LIST
`
`
`
`
`
`Mail Stop "PATENT BOARD"
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`1 Case IPR2015-01820 has been joined with this proceeding.
`
`
`
`
`
`Exhibit #
`
`Description
`
`IPR2015-00547
`Petitioners’ Exhibit List
`
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`1007
`
`1008
`
`1009
`
`1010
`
`Reardan et al., U.S. Patent No. 7,765,107 (filed Apr. 1, 2005;
`issued Jul. 27, 2010)
`
`File History for U.S. Patent No. 7,765,107 (filed Apr. 1, 2005;
`issued Jul. 27, 2010)
`
`FDA Peripheral & Central Nervous System Drugs Advisory
`Committee, Transcript and Slides (“Advisory Committee
`Transcript and Slides”) (July 13, 2001)
`
`FDA Peripheral & Central Nervous System Drugs Advisory
`Committee, Briefing Information, Division of
`Neuropharmacological Drug Products Preliminary Clinical
`Safety Review of NDA 21-196 (“Preclinical Safety Review”)
`(July 13, 2001)
`
`FDA Peripheral & Central Nervous System Drugs Advisory
`Committee, Briefing Information, Briefing Booklet (“Briefing
`Booklet”) (July 13, 2001)
`
`FDA Peripheral & Central Nervous System Drugs Advisory
`Committee, Briefing Information, Xyrem Prescription and
`Distribution Process Video and Transcript (“Xyrem Video and
`Transcript”) (July 13, 2001)
`
`Declaration of Dr. Robert J. Valcuk, Ph.D., R.Ph.
`
`Curriculum Vitae of Dr. Robert J. Valuck, Ph.D., R.Ph.
`
`Shulman, S., “The Broader Message of Accutane,” Am. J. of
`Public Health, 79:1565-1568 (1989)
`
`Lilly et al., U.S. Patent Appl. Pub. No. 2004/0176985 (filed
`Mar. 18, 2004; published Sep. 9, 2004) (“Lilly”)
`
`2
`
`
`
`IPR2015-00547
`Petitioners’ Exhibit List
`
`Exhibit #
`
`Description
`
`1011
`
`1012
`
`1013
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`Honigfeld, G., “Effects of the Clozapine National Registry
`System on Incidence of Deaths Related to Agranulocytosis,”
`Psychiatric Services, 47:52-56 (1996)
`
`Burleson, K., “Review of computer applications in institutional
`pharmacy—1975-1981,” Am. J. Hosp. Pharm., 39:53-70 (1982)
`
`Zeldis, J., et al., “S.T.E.P.S.™: A Comprehensive Program for
`Controlling and Monitoring Access to Thalidomide,” Clin.
`Therapeutics, 21:319-330 (1999)
`
`“Managing the Risks from Medical Product Use: Creating a
`Risk Management Framework,” Report to the FDA
`Commissioner from the Task Force on Risk Management, U.S.
`Dept. of Health and Human Services, Food and Drug
`Administration (1999)
`
`66 Fed. Reg. 24391
`
`File History for U.S. Patent No. 7,668,730 (filed Dec. 17, 2002;
`issued Feb. 23, 2010)
`
`FDA Center for Drug Evaluation and Research, 2001 FDA
`Advisory Committee’s Meeting Documents by Center,
`available at
`http://www.fda.gov/ohrms/dockets/ac/01docsbc.htm
`
`Internet Archive Wayback Machine, Center for Drug Evaluation
`and Research 2001 Meeting Documents, available at
`https://web.archive.org/web/20010617210030/http://www.fda.g
`ov/ohrms/dockets/ac/cder01.htm (dated June 17, 2001)
`
`Peripheral and Central Nervous System Drugs Advisory
`Committee, Briefing Information, from FDA Central Website
`(dated July 1, 2001)
`
`3
`
`
`
`IPR2015-00547
`Petitioners’ Exhibit List
`
`Exhibit #
`
`Description
`
`1020
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`Internet Archive Wayback Machine, Center for Drug Evaluation
`and Research 2001 Meeting Documents, available at
`https://web.archive.org/web/20011004081740/http://www.fda.g
`ov/ohrms/dockets/ac/cder01.htm (dated Oct. 4, 2001)
`
`Orange Book Entries for Xyrem®, available at
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cf
`m?Appl_No=021196&TABLE1=OB_Rx; and
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.
`cfm?Appl_No=021196&Product_No=001&table1=OB_Rx
`
`Rome, E., “It’s a rave new world: Rave culture and illicit drug
`use in the young,” Cleveland Clinic J. of Med., 68:541-550
`(2001)
`
`FDA, Center for Drug Evaluation and Research, NDA 21-196,
`Approved Labeling, available at
`http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-
`196_Xyrem_prntlbl_P1.pdf
`
`INTENTIONALLY LEFT BLANK
`
`INTENTIONALLY LEFT BLANK
`
`INTENTIONALLY LEFT BLANK
`
`FDA’s Center for Drug Evaluation and Research, Advisory
`Committees CDER 2001 Meeting Documents, available at
`http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Peripheral%
`20&%20Central%20Nervous 1/
`
`1028
`
`Affidavit from the Internet Archive Wayback Machine
`
`1029
`
`Mitchell, A., et al., “A Pregnancy-Prevention Program in
`Women of Childbearing Age Receiving Isotretinoin,” The New
`England Journal of Medicine, 333:101-106 (1995)
`
`1030
`
`INTENTIONALLY LEFT BLANK
`
`4
`
`
`
`IPR2015-00547
`Petitioners’ Exhibit List
`
`Exhibit #
`
`Description
`
`1031
`
`INTENTIONALLY LEFT BLANK
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`1039
`
`1040
`
`1041
`
`1042
`
`1043
`
`Scrima, L., et al., “Efficacy of Gamma-Hydroxybutyrate versus
`Placebo in Treating Narcolepsy-Cataplexy: Double-Blind
`Subjective Measures,” Biol. Psychiatry, 26:331-343 (1989)
`
`Talk About Sleep, “An Interview with Orphan Medical about
`Xyrem®,” available at http://www.talkaboutsleep.com/an-
`interview-with-orphan-medical-about-xyrem/ (“Talk About
`Sleep”) (Feb. 12, 2001)
`
`Honigfeld, G., et al., “Reducing Clozapine-Related Morbidity
`and Mortality: 5 Years of Experience with the Clozaril National
`Registry,” J. Clin. Psych. 59 (suppl. 3): 3-7 (“Honigfeld”)
`(1998)
`
`Elsayed et al., U.S. Patent No. 6,045,501 (filed Aug. 28, 1998;
`issued Apr. 4, 2000) (“Elsayed”)
`
`U.S. Provisional Appl. No. 60/332,807 (filed Nov. 14, 2001)
`
`Jazz Pharmaceuticals Form 10-K, (Annual Report) for the
`period ending December 31, 2014
`
`Complaint for Patent Infringement, Jazz Pharmaceuticals, Inc.,
`v. Par Pharmaceuticals, Inc., 2:13-cv-07884 (December 27,
`2013)
`
`Declaration of Barry Gilman
`
`Declaration of Steven A. Maddox In Support of Pro Hac Vice
`Motion
`
`INTENTIONALLY LEFT BLANK
`
`INTENTIONALLY LEFT BLANK
`
`INTENTIONALLY LEFT BLANK
`
`5
`
`
`
`IPR2015-00547
`Petitioners’ Exhibit List
`
`Exhibit #
`
`Description
`
`1044
`
`1045
`
`1046
`
`1047
`
`1048
`
`1049
`
`1050
`
`1051
`
`1052
`
`1053
`
`1054
`
`1055
`
`1056
`
`1057
`
`1058
`
`1059
`
`INTENTIONALLY LEFT BLANK
`
`Expert Questions Answered by Bryan Bergeron, Expert EV
`(2011)
`
`INTENTIONALLY LEFT BLANK
`
`File History Excerpt, U.S. Patent No. 7,668,730, Appeal Brief
`(filed July 18, 2007)
`
`File History Excerpt, U.S. Patent No. 7,668,730, Specification
`
`Webster’s Third New International Dictionary Excerpt
`
`Webster’s II New College Dictionary Excerpt
`
`Roget’s II The New Thesaurus 3d Edition Excerpt
`
`INTENTIONALLY LEFT BLANK
`
`Deposition Transcript of Bryan Bergeron, Vol. 1 (Jan. 21, 2016)
`
`Deposition Transcript of Bryan Bergeron, Vol. 2 (Jan. 22, 2016)
`
`Deposition Transcript of Joseph Dipiro, Day 1 (Feb. 3, 2016)
`
`Deposition Transcript of Joseph Dipiro, Day 2 (Feb. 4, 2016)
`
`FDA Guidance for Industry (Jan. 1, 2000)
`
`Third Affidavit of Christopher Butler (Internet Wayback
`Machine)
`
`Email to Petitioners’ Counsel from F. Calvosa regarding Patent
`Owner Jazz Pharmaceuticals, Inc.’s supplemental evidence
`(Nov. 30, 2015)
`
`6
`
`
`
`IPR2015-00547
`Petitioners’ Exhibit List
`
`Exhibit #
`
`Description
`
`Email to all counsel of record from the Board allowing
`Petitioners to file a 7-page motion under 37 C.F.R. § 42.5(c)(3)
`requesting late filing of their evidence objections (Mar. 18,
`2016)
`
`Order, Jazz Pharms., Inc. v. Roxane Laboratories, Inc., 2:10-cv-
`006108 (D.N.J. Mar. 24, 2014)
`
`Email to all counsel of record from the Board allowing
`Petitioners to file Responses to Patent Owner’s Requests for
`Rehearing pursuant to 37 C.F.R. § 42.71(d)
`
`1060
`
`1061
`
`1062
`
`
`
`7
`
`
`
`IPR2015-00547
`Petitioners’ Exhibit List
`
`
`Respectfully Submitted,
`MADDOX EDWARDS, PLLC
`
`
`
`
`____________________________________
`Matthew C. Ruedy
`Registration No. 64,823
`1900 K Street NW – Suite 725
`Washington, D.C. 20006
`(202) 830-0779
`mruedy@meiplaw.com
`Attorney for Petitioners Amneal
`Pharmaceutical LLC and Par
`Pharmaceutical, Inc.
`
`
`
`Date: September 16, 2016
`
`
`8
`
`
`
`IPR2015-00547
`Petitioners’ Exhibit List
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e))
`
`
`
`The undersigned hereby certifies that the above-captioned "Amneal
`
`Pharmaceuticals LLC and Par Pharmaceutical, Inc.’s Exhibit List," along with
`
`Exhibits 1062, were served in their entirety on September 16, 2016, upon the
`
`following parties via email:
`
`F. Dominic Cerrito
`QUINN EMANUEL URQUHART &
`SULLIVAN LLP
`51 Madison Avenue
`22nd Floor
`New York, NY 10010
`nickcerrito@quinnemanuel.com
`
`John V. Biernacki
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, OH 44114
`jvbiernacki@jonesday.com
`
`
`
`
`
`Respectfully Submitted,
`MADDOX EDWARDS, PLLC
`
`
`
`
`
`Date: September 16, 2016
`
`
`
`
`________________________________
`Matthew C. Ruedy
`Registration No. 64,823
`1900 K Street NW – Suite 725
`Washington, D.C. 20006
`(202) 830-0779
`mruedy@meiplaw.com
`Attorney for Petitioners Amneal
`Pharmaceutical LLC and Par
`Pharmaceutical, Inc.
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
